Objective
To evaluate the clinical effectiveness and safety of stents loaded with 125I seeds compared to conventional stents.
Methods
Literatures were searched in PubMed, EMbase, Cochrane Library, CBM, CNKI, Wanfang Data and other electronic databases from inception to November 2016. Two reviewers independently screened the literature according to the inclusion and exclusion criteria, extracted data and assessed quality of the included studies independently. Meta-analyses were performed using RevMan 5.3.
Results
A total of five RCTs and 14 CCTs involving 1 211 patients were included. The mean survival time of the 125I stent group was significantly higher than that of the control group[mean difference=4.11, 95% CI (2.16-6.07)P <0.001 ] . The incidence of restenosis after 3: The available data showed that the incidence of re-staging of 125I stent in the treatment group was lower than that of the normal stent group[RR=0.23, 95%CI(0.12-0.62), P=0.002]. Postoperative bleeding[RR=0.80, 95%CI (0.52-1.23), P=0.30]; Postoperative pain[RR=1.06, 95%CI(90.88-1.27), P=0.55]; postoperative stent shift [RR=0.53, 95%CI(0.27-1.05), P=0.07]. The difference of incidence of complications was not statistically significant.There was no difference in the incidence of complications between the two groups.
Conclusions
The available data suggest that 125I stent is superior to common stent in the treatment of advanced esophageal cancer. There are no differences found in the incidence of complications between 125I stent and conventional stent. However, due to the limited quality of the included studies, more high-quality and multicenter-based studies are needed to verify the above conclusion.
Key words:
Esophagus cancer; 125I seeds; Efficacy-based; Safety; Meta analysis
Objective
To systematically evaluate the efficacy and safety of 125I seed implantation for treatment of advanced pancreatic cancer.
Methods
An electronic literature search was performed about randomized controlled trials(RCTs) of 125I implantation for treamtent of advanced pancreatic cancer in CNKI, Wanfang Data, CBM, Cochrane Library, PubMed and Embase (from the date of building the database to November 2016). Two investigators independently screened literature, extracted data and assessed the risk bias of included studies, and the Meta-analysis was performed by using Revman 5.3 software.
Results
There were 12 RCTs (n=689) included. Meta-analysis showed that the objective respond rate(ORR) (OR=3.24, 95%CI 2.33-4.52, P<0.001), the 6-month survival rate(OR=3.61, 95%CI 1.53-8.52, P=0.003), the 12-month survival rate(OR=4.80, 95%CI 2.40-9.57, P<0.001) and the relief rate of pain were higher than those in the control group. However, there were no significant differences between both groups in the 2-year survival rate and the adverse reaction rate, which were (OR=2.36, 95%CI 0.47-11.74, P=0.29) and (OR=4.94, 95%CI 1.05-23.23, P=0.04), respectively.
Conclusions
The limited current evidence showed that 125I implantation for treatment of advanced pancreatic cancer is effective and safety. 125I implantation can improve the ORR, short-time survival rate and pain relief rate. In addition, there was no significant increase in the incidence of related adverse events except for seed malposition. Although the quality and quantity of evidences is limited, it merits further study to provide high quality evidences.
Key words:
125I seed; Brachytherapy; Pancreatic cancer; Systematic review; Meta analysis
This article describes authors design of high-precision edge trimmer and his commissioning experience,analyzes factors affecting trimming quality and puts forward the measure for improving trimming quality.
Microtubule-interacting and trafficking domain containing 1 (MITD1) is associated with abscission during cytokinesis. However, systematic investigation into its role in cancer is lacking. Therefore, we explored the pan-cancer role of MITD1 using multiple databases. Expression and clinical survival, immunological, and enrichment analyses were performed using R packages and online tools. For breast cancer, single-cell level analysis, immunochemistry, and in vitro experiments were performed to explore the mechanism of MITD1. A nomogram was established to predict the prognosis of patients with breast cancer and evaluate the immunotherapy biomarker based on two datasets. In some cancers, high MITD1 expression was associated with a more favorable prognosis. For instance, it inhibited tumor cell proliferation and migration in breast cancer. MITD1 may regulate cancer development by altering the tumor microenvironment, and MITD1 expression may predict the response to immune checkpoint blockade, platinum, and poly ADP-ribose polymerase inhibitor therapies. Our nomogram was used to determine the prognosis of patients with breast cancer. MITD1 can also predict the response to immunotherapy. Our first pan-cancer study of MITD1 has shown that it plays different roles in cancer development and therapy. In breast cancer, MITD1 inhibited cell proliferation and migration and serves as a new biomarker.
'/%3e%3cuse xlink:href='%23a' transform='rotate(23.036 .093 25.536)'/%3e%3cuse xlink:href='%23a' transform='rotate(45.87 1.273 16.18)'/%3e%3cuse xlink:href='%23a' transform='rotate(69.945 .996 12.078)'/%3e%3cuse xlink:href='%23a' transform='rotate(20.66 -19.689 31.932)'/%3e%3c/svg%3e)